To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302)

Marginal Zone Lymphoma (MZL) Clinical Trial

Official title:
A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Parsaclisib Plus Investigator's Choice of Either Rituximab or Obinutuzumab in Participants With Relapsed or Refractory Follicular Lymphoma and Marginal Zone Lymphoma

Status Withdrawn

Clinical Trial Summary

This is a Phase 3, double-blind, randomized, placebo-controlled, multicenter study of parsaclisib plus investigator's choice of either rituximab or obinutuzumab versus placebo plus investigator's choice of rituximab or obinutuzumab for the treatment of participants with R/R FL or MZL. The Participants will be stratified in a 1:1 randomization ratio by investigator's choice of rituximab or obinutuzumab prior to randomization, time since last antilymphoma therapy (≤ 2, > 2 years), and disease histology (MZL or FL) .

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04796922
Study type	Interventional
Source	Incyte Corporation
Contact
Status	Withdrawn
Phase	Phase 3
Start date	December 30, 2022
Completion date	August 25, 2032

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06043011` - Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms
Recruiting	`NCT03869619` - REal World Data in LYmphoma and Survival in Adults
Active, not recruiting	`NCT04830137` - A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies	Phase 1
Recruiting	`NCT03547115` - A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML	Phase 1
Active, not recruiting	`NCT03625037` - First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma	Phase 1/Phase 2
Recruiting	`NCT03265158` - Blood Immunophenotyping in Staging of Indolent B-cell Lymphomas V1.0	N/A
Enrolling by invitation	`NCT04488354` - Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T	Phase 1
Recruiting	`NCT05720052` - A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma	Phase 1/Phase 2
Recruiting	`NCT06149286` - A Trial to Learn if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Participants With Follicular Lymphoma and Marginal Zone Lymphoma	Phase 3
Active, not recruiting	`NCT04450069` - CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies	Phase 1
Recruiting	`NCT05131022` - A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies	Phase 1